Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   16/03/2026
3,610 USD (+4,03%)
(+4,03%)   16/03/2026

4 maart 2026 · Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results · Persbericht

26 februari 2026 · Transactions of Managers and Closely Associated Persons · Persbericht

11 februari 2026 · Alvotech Announces Increase in Number of Own Shares · Persbericht

5 februari 2026 · Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® · Persbericht

2 februari 2026 · Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates · Persbericht

29 januari 2026 · Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg · Persbericht

7 januari 2026 · Correction: Transactions of Managers and Closely Associated Persons · Persbericht

6 januari 2026 · Transactions of Managers and Closely Associated Persons · Persbericht

6 januari 2026 · Alvotech announces planned CEO succession and leadership transition · Persbericht

31 december 2025 · Alvotech Secures Term Loan Facility of USD 100 Million · Persbericht

29 december 2025 · Changes in company's own shares · Persbericht

22 december 2025 · Alvotech’s Financial Calendar for 2026 · Persbericht

22 december 2025 · Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma · Persbericht

19 december 2025 · Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® · Persbericht

17 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

17 december 2025 · Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering · Persbericht

16 december 2025 · Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance · Persbericht

11 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

3 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

24 november 2025 · Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area · Persbericht

Mijn selecties